Figure 2.
In vitro and clinical response to venetoclax. (A) Mononuclear cells were treated with 300nM of venetoclax for 24 hours. Cells were then stained with an anti-CD138-PE mAb. Plasma cell death was assessed by the loss of CD138 expression. Cell death percentage was calculated relative to control (ct) cells. FSC: forward scatter. (B) PR: partial response; VGPR: very good partial response.